Efficacy of ARISTA-AH for Restoring Hemostasis Following Posterior Long-segment Spinal Fusion.
Launched by POLYCLINIQUE BORDEAUX NORD AQUITAINE · Apr 11, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a product called ARISTA-AH, which is being tested to see how well it helps stop bleeding after a specific type of spine surgery known as posterior long-segment spinal fusion. This surgery involves connecting several vertebrae in the lower back to correct problems like spinal deformities. The goal is to find out if ARISTA-AH can effectively restore hemostasis, which means stopping bleeding during and after the surgery.
To be eligible for this trial, patients must be between the ages of 65 and 74 and scheduled for a specific type of spine surgery that involves at least five connected vertebrae. They must also have a surgical drain placed at the site of the operation to help manage fluid. However, patients who are under 18, have certain blood disorders or infections, are pregnant, or have allergies to the study device cannot participate. Those who join the trial will help researchers learn about the effects of ARISTA-AH and how it can improve safety during spine surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patient eligible to a posterior lumbar or thoraco-lumbar long-segment spinal fusion.
- 2. Surgery targeting at least 5 adjacent vertebra combined with one of the following procedure:
- • 1. Intersomatic bone graft;
- • 2. Pedicle substraction osteotomy;
- • 3. Any other intervertebral osteotomy (e.g. Smith-Petersen osteotomy);
- • 3. The use of a surgical drain inserted at the operative site is mandatory (suction drain and other drain are eligible);
- Exclusion Criteria:
- • 1. Subject under the age of 18 years old;
- • 2. Subject with a known haemostatic disorder;
- • 3. Subject with any infection or any immune system disorder;
- • 4. Subject not eligible to a posterior spinal surgery;
- • 5. Subject with a known allergy or any contraindication to the use of the study device;
- • 6. Currently pregnant or planning pregnancy;
- • 7. Prisoner or a ward of the state;
- • 8. Subject no willing to participate in the study;
- • 9. Subject not affiliated to a social security insurance.
About Polyclinique Bordeaux Nord Aquitaine
Polyclinique Bordeaux Nord Aquitaine is a leading healthcare institution dedicated to providing high-quality medical services and advancing clinical research. Located in the vibrant region of Bordeaux, France, the polyclinic specializes in a range of healthcare disciplines, offering comprehensive patient care and innovative treatment options. With a commitment to clinical excellence and patient-centered research, the polyclinic actively sponsors and conducts clinical trials aimed at improving therapeutic outcomes and enhancing medical knowledge. Its multidisciplinary team of experienced professionals collaborates closely with researchers and healthcare providers to ensure the highest standards of safety and efficacy in all clinical studies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bordeaux, , France
Patients applied
Trial Officials
Jean Charles LE HUEC, M.D., PhD
Principal Investigator
VERTEBRA Institute, Polyclinique Bordeaux Nord Aquitaine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials